Late-Onset Guillain-Barré Syndrome and Right Facial Nerve Palsy after COVID-19 Infection

Here, we present a case of late-onset Guillain-Barré syndrome (GBS) associated with COVID-19. A 70-year-old woman presented with ascending paralysis and right lower motor neuron facial weakness 2 months after COVID-19 infection. Test results for SARS-CoV-2 immunoglobulin were positive at the time of presentation. Lumbar puncture showed albuminocytological dissociation, and electrophysiology showed features of demyelination with secondary axon loss. In the published literature on GBS associated with COVID-19, almost all patients presented with neurological symptoms 1–4 weeks after the infection. GBS can be an early or late manifestation after COVID-19. Patients with signs of paraparesis and facial weakness after COVID-19 should be carefully evaluated for immune-mediated central and peripheral nervous system disorders.

[1]  F. Valzania,et al.  Facial palsy during the COVID‐19 pandemic , 2020, Brain and behavior.

[2]  G. Gigli,et al.  HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome , 2020, Neurological Sciences.

[3]  C. Soares,et al.  Peripheral facial nerve palsy associated with COVID-19 , 2020, Journal of NeuroVirology.

[4]  K. Rahimi.  Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports , 2020, Neurological Sciences.

[5]  J. Vallat,et al.  Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[6]  H. Tumani,et al.  Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases , 2020, Journal of Neurology.

[7]  J. Antel,et al.  Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic , 2020, Journal of the Neurological Sciences.

[8]  Zhi-qiang Zhou,et al.  Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms , 2020, Journal of Neurology.

[9]  Y. Goh,et al.  Pearls & Oy-sters: Facial nerve palsy in COVID-19 infection , 2020, Neurology.

[10]  F. Baldanti,et al.  Guillain–Barré Syndrome Associated with SARS-CoV-2 , 2020, The New England journal of medicine.

[11]  J. Benito-León,et al.  Miller Fisher syndrome and polyneuritis cranialis in COVID-19 , 2020, Neurology.

[12]  N. Karimi,et al.  Guillain Barre syndrome associated with COVID-19 infection: A case report , 2020, Journal of Clinical Neuroscience.

[13]  Dingding Shen,et al.  Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? , 2020, The Lancet Neurology.

[14]  Tsutomu Hashikawa,et al.  The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients , 2020, Journal of medical virology.

[15]  H. Nakajima,et al.  Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels , 2020, BMC Neurology.

[16]  S. Quijano-roy,et al.  Acute axonal neuropathy subtype of Guillain Barré syndrome in a French pediatric series: Adequate follow-up may require repetitive electrophysiological studies. , 2017, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[17]  P. De Cruz,et al.  Guillain-Barré syndrome in association with antitumour necrosis factor therapy: a case of mistaken identity , 2017, BMJ Case Reports.

[18]  N. Yuki,et al.  Polyclonal IgM and IgA block in vitro complement deposition mediated by anti-ganglioside antibodies in autoimmune neuropathies. , 2016, International immunopharmacology.

[19]  G. Fink,et al.  Posterior reversible encephalopathy syndrome and stroke after intravenous immunoglobulin treatment in Miller-Fisher syndrome/Bickerstaff brain stem encephalitis overlap syndrome. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[20]  R. Verma,et al.  Unilateral facial palsy in Guillain-Barre syndrome (GBS): a rare occurrence , 2012, BMJ Case Reports.

[21]  H. Hartung,et al.  Guillain-Barré syndrome after exposure to influenza virus. , 2010, The Lancet. Infectious diseases.

[22]  E. Papadopoulos,et al.  Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. , 2006, Arthritis and rheumatism.

[23]  P. Schmitz,et al.  The spectrum of antecedent infections in Guillain-Barré syndrome , 1998, Neurology.

[24]  B. Soliven.  Animal models of autoimmune neuropathy. , 2014, ILAR journal.

[25]  R. Humbel.  [Campylobacter jejuni infection and Guillain-Barré syndrome]]. , 2010, Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg.

[26]  S. Kuwabara.  Guillain-Barré syndrome: epidemiology, pathophysiology and management. , 2004, Drugs.